Information Provided By:
Fly News Breaks for October 4, 2018
HZNP
Oct 4, 2018 | 14:05 EDT
After Horizon Pharma announced 72-week durability data for its phase 2 trial of teprotumumab in treatment of thyroid eye disease, or TED, Goldman Sachs analyst Dana Flanders called the data "highly encouraging" and supportive of the drug being competitive to, and potentially better than, the current medical standard of care. The analyst, who forecasts risk-adjusted sales of greater than $200M by 2025 for teprotumumab, said those estimates are likely still conservative. Flanders reiterates a Buy rating on Horizon shares with a $26 price target.
News For HZNP From the Last 2 Days
There are no results for your query HZNP